FUSN PHAR

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform together with its Fast-Clear linker technology. Its technology enables it to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. The Company's lead product candidate is FPI-1434, that utilizes Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor I receptor (IGF-1R) with alpha emitting isotope actinium-225.